VLGC Virologic (MM)

ViroLogic to Host Panel on Personalized Medicine at BIO 2004 SOUTH SAN FRANCISCO, Calif., June 3 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (NASDAQ:VLGC) today announced that Bill Young, Chairman and CEO, will moderate a panel entitled "Making Personalized Medicine a Reality" at BIO 2004 on Tuesday, June 8, 2004, 4:00 - 5:30 p.m. EDT in Room 2005 West Building, 747 Howard Street in San Francisco. The panel will also feature executives from other leading biotechnology companies focused on personalized medicine for cancer, infectious and other serious diseases. The panel includes: -- Gordon Ringold, Co-founder, Chairman & CEO, SurroMed, Inc. -- Steven Shak, M.D., Chief Medical Officer, Genomic Health, Inc. -- Sharat Singh, Ph.D., Chief Technical Officer, ACLARA Biosciences, Inc. -- Jeannette Whitcomb, Ph.D., Vice President, Operations, ViroLogic, Inc. -- Emily Winn-Deen, Senior Director, Genomics Business, Roche Molecular Diagnostics "Tailoring therapy to the individual genetic make-up of the patient or the disease-causing agent maximizes the likelihood that treatment will be not only successful, but also potentially more cost-effective," said Young. "Informed and judicious use of drugs can save the health-care system millions of dollars each year. However, the promise of personalized medicine is dependent on the use of diagnostic and disease-monitoring technologies to match the right patient with the right drug." This panel will explore current examples of these technologies and what the industry expects to see in the near future. Interviews and one-on-one briefings with panel participants are available upon request by contacting Carolyn Bumgardner Wang at 415-362-5018 or . About ViroLogic ViroLogic (the "Company") is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases such as AIDS and hepatitis. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines targeted at emerging drug-resistant viruses. More information about the Company and its technology can be found on its web site at http://www.virologic.com/ . Certain statements in this press release are forward-looking, including statements relating to personalized medicine. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the Company's products may not perform in the same manner as indicated in this press release, whether ViroLogic successfully introduces new products, whether others introduce competitive products, the risk that the Company's products for patient testing may not continue to be accepted or that increased demand from drug development partners may not develop as anticipated, the risk that gross margins may not increase as expected, the risk that ViroLogic may not continue to realize anticipated benefits from its cost-cutting measures, the timing of pharmaceutical company clinical trials, whether payors will authorize reimbursement for its products, whether the FDA or any other agency will decide to regulate ViroLogic's products or services, whether the Company will encounter problems or delays in automating its processes, whether ViroLogic successfully introduces new products, whether others introduce competitive products, whether intellectual property underlying the Company's PhenoSense technology is adequate, whether licenses to third party technology will be available, whether ViroLogic is able to build brand loyalty and expand revenues, and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of other factors that may cause ViroLogic's actual events to differ from those projected, please refer to the Company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. DATASOURCE: ViroLogic, Inc. CONTACT: Karen Wilson, CFO of ViroLogic, Inc., +1-650-624-4164, or Web site: http://www.virologic.com/

Copyright